What is required to evaluate the impact of pharmaceutical reference pricing?

Applied Health Economics and Health Policy

Volumn 4, Issue 2, 2005, Pages 87-98

  Puig Junoy, Jaume ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b DEPARTMENT OF ECONOMICS AND BUSINESS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EMPIRICISM; HEALTH SERVICE; QUESTIONNAIRE; SENSITIVITY ANALYSIS; SOCIAL WELFARE;

COST CONTROL; ECONOMICS, PHARMACEUTICAL; EVALUATION STUDIES; INSURANCE, HEALTH, REIMBURSEMENT; SPAIN;

EID: 24944478160     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200504020-00003     Document Type: Article

References (19)

1. Jönsson B. Reference pricing: central economic and policy issues. In: López-Casasnovas G, Jönsson B, editors. Reference pricing and pharmaceutical policy: perspectives on economics and innovation. Barcelona: Springer, 2001
2. Huskamp HA, Rosenthal MB, Frank RG, et al. The Medicare prescription drug benefit: how will the game be played? Health Aff 2000; 19 (2): 8-23
3. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87-123
4. Danzon P. Reference pricing: theory and evidence. In: López-Casasnovas G, Jönsson B, editors. Reference pricing and pharmaceutical policy: perspectives on economics and innovation. Barcelona: Springer, 2001
5. Ioannides LL, Ibrahim E, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilization and health outcomes. Pharmacoeconomics 2002; 20 (9): 577-91
6. Blundell R, Costa Dias M. Evaluation methods for non-experimental data. Fisc Stud 2000; 21 (4): 427-68
7. Puig-Junoy J. Evaluación de los efectos de los precios de referencia: revisión metodológica e implicaciones para la política farmacéutica. Madrid: Documento de Trabajo de la Fundación FSIS, 2003
8. Burtless G. The case for randomized field trials in economic and policy research. J Econ Perspect 1995; 9 (2): 63-84
9. Vera-Hernández M. Evaluando intervenciones sanitarias sin experimentos. Gac Sanit 2003; 17 (3): 238-48
10. Garattini L, Giuliani G, Chiara G. Is reference pricing effective in cost containment? The German experience, 1989-1992. Pharma Pricing Review 1997; 2 (7): 131-5
11. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 44: 73-85
12. Thomas MC, Mann DM. The impact of reference pricing on clinical lipid control. N Z Med J 1998; 111: 292-4
13. Narine L, Senathirajah M, Smith T. Evaluating reference-based pricing: initial findings and prospects. CMAJ 1999; 161: 286-8
14. Zweifel P, Crivelli L. Price regulation of drugs: lessons from Germany. J Regul Econ 1996; 10: 257-73
15. Bourgault C, Elstein E, Le Lorier J, et al. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting enzyme inhibitors. CMAJ 1999; 161: 255-60
16. Atella V. Drug cost containment policies in Italy: are they effective in the long run? The case of minimum reference price. Health Policy 2000; 50: 197-218
17. Heckman JJ, Lalonde RJ, Smith JA. The economics and econometrics of active labor market programs. In: Ashenfelter A, Card D, editors. Handbook of labor economics. Vol. 3. Amsterdam: Elsevier, 1999
18. Dickson M, Redwood H. Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics 1998; 14 (5): 471-9
19. Schneeweiss S, Schöffski O, Selke GW. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 1998; 44: 253-60